BioNTech Announces First Quarter 2024 Financial Results and Corporate Update

Advancing toward goal of ten or more potentially registrational trials running by the end of 2024: first patient dosed in Phase 3 clinical trial evaluating BNT323/DB-1303 in HR+ HER2-low...

Related Keywords

Germany ,China ,United States ,American ,German ,Biontech Fixvac ,Annemarie Hanekamp ,Sean Marett ,Genmabas Genmab ,Fosun Pharma ,Jens Holstein ,Ugur Sahin ,James Ryan ,Company Management Board ,Biontech Innovative Manufacturing Services Gmb ,American Society Of Clinical Oncology ,Duality Biologics Suzhou Co ,Genentech Inc ,Exchange Commission ,Pfizer Inc ,Drug Administration ,Roche Group ,Instadeep Ltd ,Pfizer ,Influenza Combination Vaccine Program ,Medilink Therapeutics Suzhou Co Ltd ,Biotheus Inc ,Genentech ,American Association For Cancer Research ,Roche Group Genentech ,German Central Bank Deutsche Bundesbank ,Biontech Group ,American Association ,Cancer Research ,Annual Meeting ,American Society ,Clinical Oncology ,First Quarter ,Diluted Earnings ,Technologies Gmbh ,Innovative Manufacturing Services ,Year Expenses ,United States Securities ,German Central Bank ,Deutsche Bundesbank ,Key Post Period End Events ,Human Epidermal Growth Factor ,Duality Biologics ,Breakthrough Therapy ,Hormone Receptor Positive ,Fast Track ,Medilink Therapeutics ,Investigational New Drug ,Key Post Period End ,Autolus Therapeutics ,Management Board ,Chief Commercial Officer ,Chief Business ,Commercial Officer ,Chief Business Officer ,Chief Legal Officer ,General Manager ,General Meeting ,Corporate Update ,New Technologies ,Private Securities Litigation Reform Act ,Consolidated Statements ,Markets ,